

APPENDIX:

The Appendix includes the following item(s) :

- a new or amended Abstract of the Disclosure
- a Replacement Sheet for Figure _____ of the drawings
- a Substitute Specification and a marked-up copy of the originally-filed specification
- a terminal disclaimer
- a 37 CFR 1.132 Declaration
- a verified English translation of foreign priority document

ABSTRACT OF THE DISCLOSURE

Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which the receptors are involved.